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Background: People with dementia living in care homes often have complex mental health problems, disabilities and
social needs. Providing more comprehensive training for staff working in care home environments is a high national
priority. It is important that this training is evidence based and delivers improvement for people with dementia
residing in these environments. Well-being and Health for People with Dementia (WHELD) combines the most effective
elements of existing approaches to develop a comprehensive but practical staff training intervention. This optimised
intervention is based on a factorial study and qualitative evaluation, to combine: training on person-centred care,
promoting person-centred activities and interactions, and providing care home staff and general practitioners with
updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes.
Design: The trial will be a randomised controlled two-arm cluster single blind trial that will take place for nine months
across 80 care homes in the United Kingdom.
Discussion: The overarching goal of this trial is to determine whether this optimised WHELD intervention is more
effective in improving the quality of life and mental health than the usual care provided to people with dementia
living in nursing homes. This study will be the largest and best powered randomised controlled trial (RCT) evaluating
the benefits of an augmented person-centred care training intervention in care homes worldwide.
Trial registration: Current controlled trials ISRCTN62237498
Date registered: 5 September 2013
Keywords: Dementia care homes, Quality of life, Antipsychotic medication, Behavioural symptoms, Cost effectiveness,
Implementation, Person-centred care, Social interactionBackground
There are more than 750,000 people with dementia in the
United Kingdom, at least 250,000 of whom live in care
homes [1]. These are the individuals with the most
complex needs, often with cognitive and functional im-
pairments in combination with significant behavioural and
psychological symptoms [2,3]. The main staff members
providing the frontline care often have minimal formal
training, yet are being asked to undertake an extremely* Correspondence: jane.fossey@oxfordhealth.nhs.uk
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unless otherwise stated.challenging role which requires a high degree of skill. One
of the consequences of this at a national level has been
the widespread use of antipsychotic medication for people
with dementia, with widespread adverse consequences
including a significant increase in mortality [2,3].
A high priority task is to provide more comprehensive
training for staff working in care home environments,
but it is important that this training be evidence based
and deliver improvement for people with dementia res-
iding in these environments [4]. Several studies have
been undertaken evaluating person-centred care (PCC)
training as an intervention in cluster randomised con-
trolled trials (RCTs) or intervention studies with a quasi-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has indicated that PCC training does deliver some signifi-
cant benefits, including a reduction in antipsychotic use
and an improvement in symptoms of agitation [4,5]. How-
ever, benefits are inconsistent across individual studies
and, perhaps most importantly, there is no clear evidence
of an improvement in quality of life. Whilst PCC training
is of some value, there is a clear need to optimise these
interventions.
To take this work forward, the National Institute of
Health Research (NIHR) funding the Well-being and
Health for People with Dementia (WHELD) programme
undertook a factorial study to determine whether social
intervention, exercise and formal antipsychotic review
added significant benefit to PCC training. Based on the
results, an optimised intervention has been developed
combining PCC training, social intervention and a modi-
fied approach to antipsychotic review. The current study
will examine this optimised intervention in a parallel
group cluster RCT comparing the intervention to usual
care over nine months.Rationale for current study
There is strong evidence that a number of interventions
confer some benefit, but no single intervention has
achieved both an improvement of mental health and a re-
duction of antipsychotic use in people with dementia; and
none of the interventions conferred a direct benefit to the
quality of life (QoL) of people with dementia in care
homes.
The overarching goal of this programme is to determine
whether this optimised WHELD intervention, combining
PCC, promoting person-centred activities and interactions
and providing care home staff and general practitioners
with updated knowledge regarding the optimal use of psy-
chotropic medications for persons with dementia in care
homes, is more effective in improving the QoL and mental
health than usual care for people with dementia living in
nursing homes. This optimised WHELD intervention is
based on the findings of the factorial study [6] and qua-
litative evaluation designed to facilitate the design of
the current study; a multicentre, two-arm cluster RCT,
which is designed to establish the value of the WHELD
intervention.Study objectives
The primary objective is to determine whether the opti-
mised WHELD intervention will significantly improve
QoL for people with dementia in comparison to the
usual care provided in care homes.
Evaluations will be undertaken to understand the
breadth of additional benefits conferred by the interven-
tions compared with treatment as usual.Secondary objectives
Key secondary objectives will be to determine the spe-
cific impact of the optimised WHELD intervention on a
range of outcomes including mental health and unmet
needs, use of psychotropic drugs, pain, the quality of the
interaction of care staff with people with dementia, and
a person-centred environment in care home settings and
to overall provide a cost-effective, simple and practical
intervention.
Hypotheses
We hypothesise that the intervention will significantly
improve several key outcomes. Specifically, we hypothe-
sise that, compared to treatment as usual, the optimised
WHELD intervention will:
 Improve the QoL for people with dementia living in
care homes
The secondary hypotheses are that the optimised
WHELD intervention will:
 Reduce the rate of global deterioration
 Reduce agitation and other behavioural and
neuropsychiatric symptoms
 Improve mood and depression
 Reduce the use of antipsychotic and other
psychotropic drugs
 Reduce pain
 Reduce unmet needs
 Reduce mortality
 Provide a cost-effective intervention
 Improve the quality of interactions between staff
and residents
 Provide a person-centred environment in care home
settings
Methods/design
Overall design
The study design is a cluster randomised controlled,
two-arm trial to be run in up to 80 care homes. It is esti-
mated that each cluster will include a minimum of 12
participants. Each cluster in the optimised WHELD
intervention arm will receive the intervention for nine
months. Evaluations will be undertaken to understand
the breadth of benefits conferred by the intervention to
be assessed when used in comparison with the progress
of the participants residing in the care homes allocated
to the treatment as usual (TAU) trial arm.
The WHELD intervention
The optimised WHELD intervention consists of a combin-
ation of elements taken from the interventions trialled in
our previous factorial study [6] to form a single formulated,
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tion training will focus on PCC, promoting tailored person-
centred activities and interactions, and will provide care
home staff and general practitioners with updated know-
ledge regarding the optimal use and monitoring of psycho-
tropic medications for people with dementia in care homes.
The WHELD package will consist of a PCC intervention,
which primarily uses the tools developed in evidence-based
approaches for improving care in care homes, which was
shown to be effective in previous RCTs [7-9]. Additional
supplementary materials have been drawn from the best
available training manuals from a robust review of available
materials [10-12] conducted as part of the WHELD study.
The feasibility of incrementally combining these materials
was evaluated in our previous factorial study [6], and the
findings have been used to create the current optimised
intervention.
The PCC intervention has five foci:
 Embedding an understanding of dementia and PCC
 Developing the staff ’s understanding about the
relationship between an individual’s experience and
that individual’s behaviour and well-being
 Having care homes embed processes for
self-assessing how their practices deliver PCC
 Enabling staff to recognise the impact of
staff - resident interactions on the care experience
 Having staff and residents implement PCC planning
and individualised care practice based on these
principles
This intervention will use evidence-based approaches and
specific communication skills training to enhance staff-
resident interactions. The intervention will also incorporate
evidence-based approaches to encourage person-centred
activities and interaction.
The intervention will be delivered by trained research
therapists, who will receive an intensive ten-day training
package, each of whom will coordinate the delivery of the
intervention in the care homes, supported as appropriate
by senior staff at each centre. Part of the intervention will
involve the training of two lead care staff members
(WHELD Champions) in each care home over a period of
four months (one training day per month) with additional
coaching and supervision over the nine-month period, to
support their implementation of the intervention, The
intervention manual and materials will be made available
following publication of trial results and will also be submit-
ted for publication in accordance with the trial internal and
external dissemination plan.
Control arm
The control group will receive TAU. Care homes in the
control group will need to demonstrate a minimumacceptable standard of care, and this information will be
collected as part of the quality screening at the selection
stage.
An inventory of the standard of care of control arm
homes will be undertaken, in order to be able to de-
scribe the features of the homes and to document the
training they access during the course of the interven-
tion delivery period.
Monthly contact with control group care homes will
be maintained during the programme, to ensure that
Serious Adverse Event (SAE) reporting occurs.
Design and Consolidated Standards of Reporting Trials
(CONSORT) diagram
This will be a pragmatic cluster RCT testing the ex-
perimental intervention with a sample of residents with
dementia in care homes. The sample will be cluster-
randomised by care home, with all recruited residents in a
given care home being allocated to either the experimental
or control arm. Figure 1 (the design and CONSORT
diagram) shows the stages of the trial. Figure 2 shows the
programme milestones.
Number of participants and power of the study
Up to 80 suitable care homes, or units within larger
homes, will be identified, recruited and randomised, and
the minimum target participant recruitment is 12 indivi-
duals with dementia per care home. Therefore, the target
minimum sample size is 960, with a suggested upper re-
cruitment limit of approximately 1,280 (that is, 16 indivi-
duals with dementia per care home). There will be no
more than two units in any care home.
Baseline and follow-up data will be collected on all con-
sented residents who meet the inclusion criteria at each
participating care home. Taking into account the likely
loss to follow up, it is estimated that, on average, 8 of the
12 will be followed up at nine months, giving a total sam-
ple size of 640. This trial is cluster randomised to take ac-
count of the fact that the participants live together in care
homes. Re-analysis of data from previous studies suggests
that intra-home correlation coefficients rarely exceed 0.05.
As the ‘variance inflation factor’ (VIF) of this cluster ran-
domised trial [1 + (8 - 1) × 0.05] = 1.35, the likely useable
sample size of 640 participants will give 90% power using
a significance level of 5% to detect a standardised effect
size of 0.3 SDs, which is usually taken as the lowest
threshold of a clinically meaningful benefit [13].
The observed SD for our population on DEMQOL
taken from our pilot study is approximately 12. The
standard error of measurement (SEM), derived by multi-
plying the SD of the sample by the square root of one
minus its reliability coefficient, has been described as a
useful statistic for assessing individual change on health-
related QoL instruments [14]. Smith et al. [15] reported
Figure 1 Design and CONSORT diagram.
Figure 2 Flow chart of WHELD programme milestones.
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SEM for this data is 12*sqrt (1-.82) = 5.1. This provides
further support that we are measuring clinically mea-
ningful change in DEMQOL [16]. Expressing this
change as an effect size gives 5.1/12 = 0.425.
Randomisation
Care homes will be allocated to either receive the opti-
mised WHELD intervention or TAU using secure web ac-
cess to the remote randomisation centre at North Wales
Organisation for Randomised Trials in Health Clinical
Trial Unit (NWORTH CTU), at Bangor University. This
system will be set up, maintained and monitored inde-
pendently of the trial statistician or other trial staff. The
randomisation will be performed by dynamic allocation
[17] to protect against subversion while ensuring that the
trial maintains good balance to the allocation ratio of 1:1
both within each stratification variable and across the trial.
Care homes will be stratified by region and size. The sys-
tem has been coded and validated in the R statistical
package.
Outcome and study eligibility measures
All outcomes will be assessed prior to randomisation and
after nine months of the intervention. Outcome measures
will consist of questionnaires and direct observations,
using standardised, evidence-based scales and other infor-
mation obtained from an informant (the key worker or
another member of the staff who knows the participant
well). Participant and care home demographics will be col-
lected and measures taken as described in the following
paragraphs.
The DEMQOL [15] assesses the health-related quality
of life (HRQoL) for people with dementia. The measure
consists of two questionnaires. DEMQOL, conducted with
a person with dementia, is a 28-item interviewer-admi-
nistered questionnaire with a score range of 28 to 112.
DEMQOL-Proxy is a 31-item interviewer-administered
questionnaire answered by a caregiver with a score range
of 31 to 124. The DEMQOL-Proxy is the primary out-
come measure for this study. The measure is also vali-
dated as a method for calculating quality-adjusted life-year
(QALY) for health economic analysis.
The Quality of Life in Late-Stage Dementia (QUALID)
scale [18] is a reliable and valid scale, administered to
caregivers, for rating quality of life in people with late-
stage dementia. The scale measures 11 observable beha-
viours indicating activity and emotional states. Ratings are
made for observations made over the preceding seven
days. Items are rated on a five-point Likert scale with
QUALID scores ranging from 12 to 45 points; lower
scores reflect a higher quality of life (QoL).
The Clinical Dementia Rating (CDR) [19] is a validated
scale used to quantify the severity of symptoms ofdementia. Using a structured interview, six domains are
assessed in terms of a person’s cognitive and functional
performance. These include memory, orientation, judg-
ment and problem solving, community affairs, home and
hobbies, and personal care. CDR ratings are 0 for healthy
people, 0.5 for questionable dementia and 1, 2 and 3 for
mild, moderate and severe dementia. Scores in each of
these domains are combined to obtain a composite score
ranging from 0 (none) through 3 (severe).
The Functional Assessment Staging Tool (FAST) is a
validated functional assessment scale of elderly people
with dementia [20]. The FAST is an ordinal scale ran-
ging from 1 (indicating normal function) to 7 (indicating
severe dementia). Levels 6 and 7 are divided into specific
subscales yielding 16 possible ratings. Each level is indi-
cated by a functional description with adequate detail
for clinical scoring. The FAST score is derived from a
caregiver interview.
The Global Deterioration Scale (GDS) [21] is a staging
scale indicating deterioration in dementia. The scale de-
tails clinical descriptions of seven major distinguishable
stages, ranging from normal cognition to severe demen-
tia. Stages 1 through 3 are the pre-dementia stages,
While stages 4 through 7 reflect the stages of dementia.
People with clinical levels beginning with stage 5 are no
longer able to survive without assistance.
Agitation will be assessed using the Cohen-Mansfield
Agitation Inventory (CMAI) [22], which is a caregiver’s
rating questionnaire to specify agitated behaviour. The
CMAI consists of 29 items related to agitated behaviour,
each of which is rated on a seven-point scale of frequency,
from 1 = never to 7 = several times an hour. The rating is
based on a face-to-face interview with a caregiver.
Other behavioural and neuropsychiatric symptoms will
be recorded using the Neuropsychiatric Inventory Nursing
Home version (NPI-NH). The NPI is a validated struc-
tured interview assessment with the informant (care staff ),
that assesses behavioural disturbances in patients with de-
mentia [23]. This 12-item version consists of ten behav-
ioural and two neurovegetative areas. It provides both a
total score as well as scores for a number of subscales (de-
lusions, hallucinations, agitation/aggression, depression/
dysphoria, anxiety, disinhibition, elation/euphoria, apathy/
indifference, irritability, aberrant motor activity, sleep, and
appetite/eating disorders). The frequency, severity and
caregiver distress levels for each domain are measured.
The total possible maximum score is 144. A higher score
reflects increased frequency and severity of the distur-
bances. This specific version is developed for use in nurs-
ing homes, with adapted questions in the standardised
interview, and the caregiver distress assessment is adapted
to occupational disruptiveness.
Depression will be assessed using the Cornell Scale for
Depression in Dementia (CSDD). The CSDD [24] is an
Whitaker et al. Trials 2014, 15:284 Page 6 of 11
http://www.trialsjournal.com/content/15/1/284assessment of signs and symptoms of major depression
in patients with dementia. The CSDD uses a compre-
hensive interviewing approach that derives information
via semi-structured interviews with the participant and
the care staff. Many of the items to be completed during
the patient interview can be filled in after direct observa-
tion of the patient. The final ratings of the CSDD items
represent the rater's clinical impression rather than the
responses of the informant or the patient. Each item
is rated for severity on a scale of 0 to 2 (0 = absent,
1 = mild or intermittent, 2 = severe), and the item scores
are then added. Scores above 10 indicate a probable
major depression. Scores above 18 indicate a definite
major depression. Scores below 6 as a rule are associated
with absence of significant depressive symptoms.
Information on antipsychotic use (number of people
taking antipsychotics and dose) will be taken from par-
ticipants’ drug charts, as will the use of other psycho-
tropic (sedative) drugs and other medication.
The Abbey Pain Scale [25] is an observational brief in-
dicator of pain for people with end-stage dementia. The
scale is rated on six non-verbal indicators of pain, where
0 is none and 3 is severe.
The Health Questionnaire (Proxy version EQ-5D-5 L),
which is based on the EQ-5D-3 L [26] is used to enable
an additional health economic evaluation. The question-
naire is short and brief, but importantly will provide
greater comparability with other studies.
The Camberwell Assessment of Need for the Elderly
(CANE Version IV) [27] is a comprehensive assessment
assessing 24 areas of social, medical, psychological and
environmental needs. The overall rating on the CANE
will be based on all the information gathered throughout
the structured interview with the care staff and on the
information collected through looking at the case-note
reviews and observations within the care home. We will
complete this instrument only after the nine months
intervention time point.
We will use the Client Service Receipt Inventory (CSRI)
[28] to estimate the cost of service packages for each
participant in the study. Information is collected on the
current living arrangements, and use of hospital, commu-
nity-based and day services over a defined retrospective of
three months in this study. The data collected through the
CSRI will be used to calculate service costs and total costs
of care.
The Quality of Interaction Schedule (QUIS) [29] is an
observational tool which measures the quality of inte-
ractions between staff and resident and person-centred
environment in care home settings.
The Enhancing the Healing Environment (EHE) Envir-
onmental Assessment Tool [30] is a comprehensive obser-
vational assessment of the care environment. Assessors
can carry out the assessment primarily by walking throughthe home and directly observing the building and the way
it is used in practice. The EHE Environmental Assessment
Tool has been produced by the Department of Health and
King’s Fund as part of a national survey; therefore, using
this tool in our study will provide benchmarking against
national data.
Intervention fidelity
To monitor intervention fidelity, each therapist will be
required to maintain a detailed log of the type and fre-
quency of interventions and an audit of detailed inter-
vention plans describing each intervention undertaken,
audit of care plans and a supervision log.
Economic evaluation
Comprehensive data on health and social care service use
and medications used by participants in the study will be
collected using a tailored version of the CSRI. We will also
collect data on staff inputs and support received by the
study participants as part of the interventions.
Services and staff inputs will be costed as long-run
marginal opportunity costs (LRMCs) using national fig-
ures. Where national figures are not available or not
suitable, we will calculate best estimates of LRMC values
from locally collected expenditure figures. Data on in-
tervention costs and service costs will be examined
alongside data on the main outcomes in a series of cost-
effectiveness analyses. Each cost-effectiveness analysis
will be conducted from the perspective of the NHS and
social services.
Quality-adjusted life-year (QALY) gains generated from
the DEMQOL will be used in turn in a series of cost-
effectiveness analyses. The evaluation will include the
plotting of cost effectiveness acceptability curves gene-
rated from bootstrap analyses. Sensitivity analyses will ex-
plore the impact of changes in the findings in key costs
and outcome assumptions.
Care home selection: inclusion and exclusion criteria
Care homes with a high proportion of residents thought
to have dementia will be identified, screened and re-
cruited to the study as described below.
An initial search for suitable care homes will be made
using local care home directories (this will include care
homes that are part of care home research networks).
These care homes will be screened for the following in-
clusion/exclusion criteria.
Inclusion criteria:
 Care homes that identify themselves as catering for
people with dementia within their literature
 Care homes that are able to demonstrate a
minimum acceptable standard of care according to
the Care Quality Commission (CQC)
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 Less than 60% of the residents have dementia
 Care home is receiving special support from their
local authority
 Care home has failed to meet the five CQC care
home quality standards checks with more than one
black mark (at least one standard in this area was
not being met and improvements are required) or
one red mark (at least one standard in this area was
not being met and enforcement has been taken):
1. Standards of treating people with respect and
involving them in their care
2. Standards of providing care, treatment and
support which meets people’s needs
3. Standards of caring for people safely and
protecting them from harm
4. Standards of staffing
5. Standards of managementThe research teams in each study site will contact all
care homes meeting the inclusion/exclusion criteria on
the list by email, mail and/or phone call. The aims of
this exercise will be to:
 Find out whether the care home might be interested
in participating in the study; and
 Screen care homes further against secondary
exclusion criteria to determine their suitability.
Secondary exclusion criteria:
 Insufficient staffing resource. Care home unable to
provide care staff champions or staff able to act as
informants for participant assessments
 Anticipated major change. Anticipated events or
major changes anticipated to take place in the next
12 months, which might impact involvement in the
research
 Involvement in other research. Care home involved
in other research projects, which might affect their
suitability to take part in this study or place too
much burden on staff and residents
 Undergoing systematic programme of service
improvement: Care home involved in a systematic
programme of service improvement (such as
intensive Dementia Care Mapping).
Once a care home meets the inclusion/exclusion cri-
teria and the manager has given consent for the study to
take place, the identifying, consenting and baseline as-
sessments will commence. Once this process has been
completed, the researcher will randomise the care home
using NWORTH’s online randomisation system. Thenthe study site will initiate the main trial procedures at
the care home.
Care home withdrawal from the study will be consid-
ered on an individual basis with the home in the event
circumstances change following the consent procedures.Recruiting centres
Three recruiting hubs based in London and Buckinghamshire
will each aim to recruit between 20 and 25 care homes.Participant selection: inclusion, exclusion and withdrawal
criteria
All residents who would be potentially eligible for eva-
luation will be identified by the care home staff.
Inclusion for evaluation:
 All individuals residing in participating care homes
who meet diagnostic criteria for dementia and/or
score ‘1’ or greater on the CDR [19].
Exclusion from evaluation:
 Any resident from whom consent or the advice of a
consultee cannot be obtained.
Withdrawal criteria:
 Individual participants will be able to withdraw from
the study evaluation at any time.Data management and analysis
Safety reports of serious adverse events (SAEs)
Reports of SAEs will be performed according to the Na-
tional Research Ethics Service (NRES) and NHS guide-
lines for safety reporting for research other than Clinical
Trial of Investigational Medicinal Products (CTIMP).Assessment and follow-up
Assessments will be made at pre-baseline to assess the
suitability of the care homes for inclusion. This process
will include assessments to identify the total number of
participants likely to be eligible for screening. Participants
will be screened and consent obtained prior to baselining
and to the care homes being randomised. Follow-up as-
sessments will be made at nine months after commence-
ment of the intervention.Data management and analysis
It is planned that anonymous data and all appropriate
documentation will be kept securely for a period of
seven years following the completion of the trial, subject
to discussion with relevant ethics committees.
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Administrative databases will be held at the study centre.
All participants and care homes will be identified by a
unique study number; this number will be used to tag all
research data sent outside the study centre, for example to
NWORTH CTU. Quantitative research data will be
entered via a web interface to the MACRO™ research da-
tabases held at NWORTH. The research team in the study
centre will conduct primary data management, and the
secondary cleaning and preparation of the data for analysis
will be conducted by NWORTH. Consideration will be
given to the differential time between baseline assessments
and the start of intervention, adjusting for the time dif-
ferences to an analysis as necessary.
Quantitative analysis
Outcome measures for the study will be assessed at
baseline and at nine months. All the outcome measures
collected will be described and reported using appro-
priate descriptive statistics and tabular and graphical
techniques. Means with 95% confidence intervals will be
quoted and a 5% significance level will be reported.
The Consolidated Standards of Reporting Trials
(CONSORT) diagram information will be presented in
order to identify any differential dropout between the
arms of the trial.
The analysis of the quantitative outcomes will involve
a multilevel analysis of covariance (ANCOVA). Logistic
regression will be used to assess whether the missing
status can be predicted from any of the factors and co-
variates measured at baseline. The variables which are
identified to affect the missing status will be included in
the analysis model [31]. The primary outcome measure
(DEMQOL proxy) [22] and the secondary outcome mea-
sures will be analysed using the multilevel modelling ap-
proach to ANCOVA. The value at nine months will be
the response. The baseline value will be the covariate.
The key factor will be group (treatment or control). The
multilevel nature of the design will be represented by
two levels: care home and individual residents in the
care home.
Other covariates, whether at the care home level (for
example, number of residents) or the resident level (age,
gender) will be investigated to see whether they have an
effect on the response measure and included as necessary.
A full statistical analysis plan will be developed through
the course of the study.
Regulatory and management issues
Ethical approval
Ethical approval was successfully obtained from the
National Research Ethics Service (NRES) Committee
South Central - Oxford C via a central ethics application
for the research trial (Rec reference: 13/SC/0281, Protocolnumber: WHELD WP5, IRAS project ID: 128232). Site
Specific Assessments (SSAs) were completed at Guys and
St Thomas’ Hospital, Oxford Health NHS Foundation
Trust and North East London NHS Foundation Trust and
approved prior to accepting participants into the study.
The study will be conducted in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, in Helsinki 1964, and later revisions.
The study may be subject to inspection and audit by the
sponsors and other regulatory bodies to ensure adherence
to Good Clinical Practice (GCP) and the current NHS
Research Governance Framework for Health and Social
Care.
Consent
Care home managers of the participating care homes
will be provided with the inclusion criteria and asked to
identify potential participants.
All of the participants will be people with dementia
living in the participating care homes. It is therefore un-
likely that more than a very small number of potential par-
ticipants will have the capacity to provide informed
consent. The care home managers will therefore then ask
the consultee if they are happy to be contacted by the re-
search team. Initially, this will be undertaken through a
letter to the consultee and might be followed by personal
conversation, as appropriate. If permission is granted, the
research team will discuss the study in further detail with
the consultee via telephone conversations or a meeting,
depending on the preference of the individual. In addition,
the relevant information sheet will be given or posted to
the consultee for their information prior to signing the
declaration form.
If the personal consultee feels that it is appropriate for
the person to take part, but feels they potentially have
the capacity to make their own decision, an assessment
of capacity will be undertaken by a study clinician. If the
individual does have capacity, a simplified written infor-
mation sheet will be provided to the individual and the
study will be explained to the person, by a member of
the research team with appropriate training and skills,
and where possible with the next of kin also present. If
the individual wishes to take part, written consent will
be taken. In addition, as a measure of good practice,
signed assent will be requested from the consultee.
For individuals who do not have capacity, an appro-
priate member of the research team will discuss the
study in further detail with a consultee of the potential
study participant through telephone conversations or a
meeting, depending on their preference. No individuals
will participate in the evaluation without signed, written
consent from themselves or a signed declaration from
their consultee. All participants are free to withdraw
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without prejudicing further treatment. For people who
lose capacity, the consultee will be approached and the
issue of on-going participation will be discussed. If the
consultee wants the person to continue to participate,
they will be asked to sign the declaration form. Ongoing
participation would just require the completion of the
nine-month outcome assessment.
Confidentiality
The Chief Investigator will preserve the confidentiality of
participants taking part in the study and is registered
under the Data Protection Act (DPA, 1998). The research
will follow DPA guidance. Only members of the research
team will have access to the original data, which will be
stored in a locked filing cabinet. Participants’ personal de-
tails will be stored separately from the original data, and
will be kept in a separate file on a password protected
computer at the study centre. Each participant will be
assigned an identification code, which will be used in all
data storage files; these files will not contain names or any
other means of personal identification. All personal details
will be deleted on completion of the study.
Indemnity
King’s College London will be responsible for providing
indemnity for negligent liability. No provision is made for
non-negligent liability, which will be covered by the usual
procedures by NHS or the care provider as applicable.
Sponsor
King’s College London will act as the sponsor for this
study.
Funding
The National Institute of Health Research (NIHR)
Programme Grants for Applied Research are funding
this study. No per participant or per care home pay-
ments are being made as part of this study.
Study management
This study will be managed by the Programme Manage-
ment Group (PMG), as part of the overall WHELD
programme. The PMG will involve all the Principal
Investigators, the Programme/Trial Manager and a
Consumer Representative. The group will meet at three-
month intervals and additionally as required. Part of the
remit of the PMG will be to oversee overall progress of
the programme and monitor progress against mile-
stones. Any discrepancy from milestones will be high-
lighted and a plan, developed to address the difficulties,
will be instigated. For the purposes of this trial, the
PMG will be acting as the Trial Management Group
(TMG), with direct oversight of and responsibility forthis study. The Programme/Trial Manager will send a
written report to the chairman of the PMG before each
TMG meeting, detailing progress.
The Programme Steering Committee (PSC) will be re-
sponsible for overall WHELD programme governance
and reporting to the sponsor. An independent subcom-
mittee of the PSC will act as the Data Monitoring and
Ethics Committee (DMEC) for the study. Both commit-
tees will meet annually and will receive annual reports
from the Programme Manager and the Trial Statistician.
The DMEC and PSC will monitor recruitment, ethical
issues and safety and will have the ultimate responsibil-
ity for the continuation or discontinuation of the study.
The DMEC will have an Independent Clinician as chair,
a further Clinician and a Statistician. The PSC will con-
sist of six members, including a Consumer Representa-
tive. Therefore, for the purpose of this trial, the PSC will
be responsible for trial governance, reporting to the
sponsor.
The day-to-day management of the trial will be con-
ducted by the Programme/Trial Manager, who will re-
port to the Chief Investigator on a regular basis. Any
non-urgent major decisions will be made by the PMG.
Discussion
This study will be the largest and best powered RCT
evaluating the benefits of an augmented PCC training
intervention in care homes worldwide and will be the
first trial that is adequately powered to determine
whether this intervention will improve QoL. The Health
Economic component will provide the first comprehen-
sive evaluation of cost effectiveness in this type of study.
Trial status
The trial is in the recruiting phase at the time of manu-
script submission.
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